Holocene Advisors
ACRS icon

Holocene Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Holocene Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200,000
Closed -$1.62M – 706
2023
Q1 		$1.62M Buy
+200,000
New +$2.54M 0.01% 499

Other funds holding ACRS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors's ACRS Position: Q3 2023 in Review

Holocene Advisors sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 1,485,056 shares — an estimated $15.4M sold.

Holocene Advisors first reported a position in ACRS in Q1 2021 and held it in 10 quarters. The position peaked at $35.5M in Q1 2022. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

  • Holocene Advisors reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Holocene Advisors sold 1,485,056 Aclaris Therapeutics shares in Q3 2023, an estimated $15.4M.
  • Holocene Advisors first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 10 quarters.
  • Holocene Advisors's Aclaris Therapeutics position peaked at $35.5M in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on Holocene Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.